Inhibitory Fcγ Receptor Deletion Enhances CD8 T Cell Stemness, Increasing Anti-PD-1 Therapy Responsiveness in Glioblastoma Background and Objectives of the Study Glioblastoma (GBM) is an aggressive central nervous system tumor with poor prognosis, and the median survival of patients is only 14.6 months. Despite the significant efficacy of immune ch...

Fusobacterium nucleatum Promotes Anti-PD-1 Therapy in Microsatellite-Stable Colorectal Cancer Background Introduction With the rise of immune checkpoint blockade (ICB) therapy, a new dawn has emerged in cancer treatment. However, despite the approval of PD-1 targeting drugs (e.g., Pembrolizumab) for certain types of colorectal cancer (CRC) patients...